Monthly information on share capital and company voting rights

Cellectis (Euronext Growth: CLLS) published its monthly report on share capital and voting rights as of Oct 31, 2025.

Rhea-AI Summary

Cellectis (Euronext Growth: CLLS) published its monthly report on share capital and voting rights as of Oct 31, 2025.

Key figures: Total number of shares = 100,325,454; Total number of voting rights = 89,406,760. The disclosure follows Article 223-16 of the French financial markets authority general regulation and lists investor and media contact details for further information.

Argus Nov 7 session

+1.92% close to close Open Argus

Details

News Market Reaction – CLLS

On Nov 7, the day this news came out, CLLS closed 1.92% above the previous close.

Data tracked by StockTitan Argus for the Nov 7 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Nov. 07, 2025 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
10/31/2025	100,325,454	89,406,760

For further information on Cellectis, please contact:     

Media contacts:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:       

Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com  

Attachments

• Voting_Rights_PR_October_2025_EN

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are Cellectis (CLLS) total shares as of October 31, 2025?

Cellectis reported 100,325,454 total shares as of October 31, 2025.

How many voting rights does Cellectis (CLLS) have on October 31, 2025?

The company reported 89,406,760 voting rights as of October 31, 2025.

Where is the Cellectis (CLLS) share capital and voting rights disclosure filed?

The disclosure is made under Article 223-16 of the French financial markets authority general regulation.

When was the Cellectis (CLLS) monthly capital report published?

The report was published on November 7, 2025 for the position dated October 31, 2025.

Who should investors contact for questions about Cellectis (CLLS) voting rights?

Investor relations contact: Arthur Stril, Chief Financial Officer & Chief Business Officer, at investors@cellectis.com.

Does the October 2025 report show any share issuance or cancellation figures for Cellectis (CLLS)?

The report provides totals for shares and voting rights on Oct 31, 2025 but does not state any issuance or cancellation amounts in the disclosed table.